fluindione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1194 957-56-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluindione
  • previscan
  • Molecular weight: 240.23
  • Formula: C15H9FO2
  • CLOGP: 2.95
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -3.64
  • ROTB: 1

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 80 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 50
kinase-selectivity-class AXL,GRK2,PDK4,PIK3CB,RIPK1,TTK 6
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 837.25 36.73 238 4910 47078 90576221
Drug interaction 520.14 36.73 270 4878 276183 90347116
Acute kidney injury 345.46 36.73 218 4930 320169 90303130
Shock haemorrhagic 217.45 36.73 62 5086 12183 90611116
Haematoma 195.34 36.73 76 5072 38972 90584327
Anaemia 188.07 36.73 157 4991 352645 90270654
Melaena 175.00 36.73 68 5080 34729 90588570
Cerebral haematoma 149.23 36.73 37 5111 4252 90619047
Hyperkalaemia 143.08 36.73 71 5077 64893 90558406
Bradycardia 128.74 36.73 72 5076 83775 90539524
Hyponatraemia 116.56 36.73 80 5068 133458 90489841
Subdural haematoma 85.28 36.73 33 5115 16612 90606687
Abdominal wall haematoma 82.73 36.73 22 5126 3330 90619969
Hepatocellular injury 79.96 36.73 37 5111 28921 90594378
Sinus node dysfunction 72.31 36.73 22 5126 5390 90617909
Prothrombin time shortened 71.00 36.73 18 5130 2260 90621039
Overdose 67.18 36.73 62 5086 157647 90465652
Cerebral haemorrhage 65.06 36.73 34 5114 34488 90588811
Muscle haemorrhage 64.14 36.73 18 5130 3328 90619971
Cholestasis 63.45 36.73 34 5114 36265 90587034
Renal failure 62.68 36.73 55 5093 130952 90492347
Retroperitoneal haematoma 59.50 36.73 17 5131 3351 90619948
Fall 58.78 36.73 101 5047 481709 90141590
Cardiac failure 58.54 36.73 49 5099 109447 90513852
Neonatal gastrointestinal disorder 58.27 36.73 9 5139 81 90623218
Lactic acidosis 55.55 36.73 35 5113 50428 90572871
Neonatal respiratory depression 51.27 36.73 9 5139 187 90623112
Cardio-respiratory arrest 50.72 36.73 36 5112 63104 90560195
Interstitial lung disease 44.60 36.73 36 5112 76369 90546930
Drug ineffective 42.66 36.73 13 5135 1384285 89239014
Pain 42.27 36.73 4 5144 996337 89626962
Haematoma muscle 40.28 36.73 11 5137 1839 90621460
Toxic skin eruption 39.96 36.73 19 5129 15755 90607544
Hypokalaemia 38.21 36.73 42 5106 131074 90492225
Rectal haemorrhage 38.06 36.73 34 5114 82710 90540589

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 652.35 27.87 256 6583 47912 42566584
Acute kidney injury 362.74 27.87 363 6476 366974 42247522
Drug interaction 306.14 27.87 287 6552 266712 42347784
Shock haemorrhagic 193.55 27.87 79 6760 16163 42598333
Hyperkalaemia 179.52 27.87 128 6711 80330 42534166
Cerebral haematoma 176.43 27.87 56 6783 5554 42608942
Haematoma 161.02 27.87 82 6757 27941 42586555
Rectal haemorrhage 92.62 27.87 71 6768 49535 42564961
Blood lactic acid 91.96 27.87 19 6820 327 42614169
Lactic acidosis 87.17 27.87 66 6773 45195 42569301
Melaena 80.19 27.87 59 6780 38687 42575809
Cholestasis 77.05 27.87 54 6785 32825 42581671
Subdural haematoma 68.62 27.87 44 6795 23094 42591402
Bradycardia 68.12 27.87 76 6763 85408 42529088
Hepatocellular injury 65.25 27.87 43 6796 23635 42590861
Interstitial lung disease 62.92 27.87 70 6769 78392 42536104
Granulomatous rosacea 61.43 27.87 12 6827 153 42614343
Anaemia 60.08 27.87 136 6703 280142 42334354
Intraventricular haemorrhage 57.06 27.87 22 6817 3862 42610634
Toxic skin eruption 55.90 27.87 32 6807 13698 42600798
Overdose 55.45 27.87 76 6763 105188 42509308
Haemorrhagic stroke 52.40 27.87 25 6814 7377 42607119
Haematuria 50.55 27.87 54 6785 57745 42556751
Eosinophilia 50.48 27.87 42 6797 32857 42581639
Blood loss anaemia 48.72 27.87 26 6813 9710 42604786
Coma 48.55 27.87 51 6788 53503 42560993
Muscle haemorrhage 45.47 27.87 19 6820 4106 42610390
Drug reaction with eosinophilia and systemic symptoms 45.33 27.87 44 6795 42031 42572465
Traumatic haemothorax 45.28 27.87 11 6828 403 42614093
Brain stem haematoma 45.16 27.87 9 6830 128 42614368
Subarachnoid haemorrhage 44.08 27.87 28 6811 14444 42600052
Cardiorenal syndrome 41.29 27.87 12 6827 881 42613615
Cardiogenic shock 39.76 27.87 38 6801 35602 42578894
Cardiac failure 38.94 27.87 65 6774 106791 42507705
Confusional state 38.81 27.87 84 6755 167513 42446983
Cerebral haemorrhage 38.72 27.87 39 6800 38927 42575569
Drug ineffective 37.56 27.87 28 6811 630169 41984327
Ischaemic stroke 37.50 27.87 30 6809 22203 42592293
Pemphigoid 36.97 27.87 23 6816 11444 42603052
Purpura 36.22 27.87 23 6816 11856 42602640
International normalised ratio abnormal 35.17 27.87 15 6824 3408 42611088
Nephroangiosclerosis 30.87 27.87 7 6832 189 42614307
Off label use 28.07 27.87 37 6802 638298 41976198

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 1468.36 27.50 492 11638 86280 110490889
Drug interaction 780.61 27.50 549 11581 499634 110077535
Acute kidney injury 725.27 27.50 578 11552 634852 109942317
Shock haemorrhagic 406.19 27.50 141 11989 27106 110550063
Haematoma 352.40 27.50 157 11973 58319 110518850
Hyperkalaemia 327.96 27.50 197 11933 135599 110441570
Cerebral haematoma 311.42 27.50 90 12040 9542 110567627
Melaena 236.92 27.50 126 12004 68631 110508538
Anaemia 222.73 27.50 286 11844 546800 110030369
Bradycardia 189.54 27.50 148 11982 155369 110421800
Subdural haematoma 149.08 27.50 75 12055 36379 110540790
Hepatocellular injury 139.18 27.50 80 12050 50562 110526607
Lactic acidosis 138.99 27.50 100 12030 92711 110484458
Cholestasis 138.63 27.50 87 12043 64431 110512738
Rectal haemorrhage 118.42 27.50 101 12029 119732 110457437
Hyponatraemia 118.08 27.50 132 11998 217521 110359648
Overdose 115.37 27.50 135 11995 233659 110343510
Interstitial lung disease 107.21 27.50 102 12028 139232 110437937
Muscle haemorrhage 104.00 27.50 36 12094 6833 110570336
Cerebral haemorrhage 101.83 27.50 72 12058 64896 110512273
Toxic skin eruption 96.30 27.50 51 12079 27464 110549705
Cardiac failure 95.29 27.50 110 12020 187516 110389653
Blood lactic acid 93.03 27.50 19 12111 459 110576710
Blood loss anaemia 85.35 27.50 41 12089 17984 110559185
Pain 76.56 27.50 8 12122 954947 109622222
Haematuria 75.97 27.50 67 12063 82938 110494231
Cardiogenic shock 75.04 27.50 57 12073 57281 110519888
Drug reaction with eosinophilia and systemic symptoms 74.61 27.50 66 12064 82029 110495140
Haemorrhagic stroke 70.29 27.50 33 12097 13756 110563413
Drug ineffective 68.91 27.50 41 12089 1520499 109056670
Renal failure 68.55 27.50 103 12027 226471 110350698
Retroperitoneal haematoma 66.09 27.50 25 12105 6106 110571063
Eosinophilia 63.75 27.50 52 12078 57884 110519285
Prothrombin time shortened 62.60 27.50 21 12109 3625 110573544
Granulomatous rosacea 62.22 27.50 12 12118 214 110576955
Sinus node dysfunction 59.93 27.50 26 12104 9021 110568148
Intraventricular haemorrhage 57.72 27.50 22 12108 5485 110571684
Abdominal wall haematoma 56.96 27.50 22 12108 5683 110571486
Ischaemic stroke 56.15 27.50 42 12088 41221 110535948
Cardio-respiratory arrest 55.57 27.50 66 12064 115770 110461399
Coma 53.01 27.50 65 12065 117804 110459365
Subarachnoid haemorrhage 51.40 27.50 35 12095 29667 110547502
Pemphigoid 51.10 27.50 30 12100 19677 110557492
Nausea 50.90 27.50 37 12093 1235653 109341516
Epistaxis 49.35 27.50 66 12064 130306 110446863
Fatigue 49.32 27.50 37 12093 1215921 109361248
Cardiorenal syndrome 49.22 27.50 15 12115 1903 110575266
Traumatic haemothorax 47.54 27.50 12 12118 760 110576409
Fall 43.40 27.50 155 11975 603327 109973842
Off label use 41.49 27.50 63 12067 1500122 109077047
Brain stem haematoma 40.80 27.50 8 12122 156 110577013
Purpura 40.45 27.50 28 12102 24360 110552809
Gastrointestinal haemorrhage 40.06 27.50 68 12062 165450 110411719
Vascular purpura 39.29 27.50 15 12115 3756 110573413
Prothrombin time ratio decreased 38.94 27.50 12 12118 1580 110575589
Headache 38.16 27.50 25 12105 882352 109694817
Jaundice 35.65 27.50 38 12092 59198 110517971
Hypotension 33.82 27.50 130 12000 523719 110053450
Confusional state 33.33 27.50 120 12010 468560 110108609
Peripheral swelling 33.31 27.50 3 12127 404031 110173138
Hypersensitivity 33.31 27.50 3 12127 403995 110173174
Nephroangiosclerosis 32.99 27.50 8 12122 429 110576740
Dermatitis exfoliative generalised 31.91 27.50 18 12112 10954 110566215
Cardioactive drug level increased 31.88 27.50 13 12117 3869 110573300
International normalised ratio abnormal 31.74 27.50 15 12115 6342 110570827
Acute pulmonary oedema 31.74 27.50 21 12109 16975 110560194
Hypokalaemia 31.67 27.50 65 12065 182383 110394786
Sinus bradycardia 31.45 27.50 26 12104 29457 110547712
Haematoma muscle 31.22 27.50 13 12117 4077 110573092
Drug intolerance 31.01 27.50 4 12126 406508 110170661
International normalised ratio decreased 30.90 27.50 16 12114 8220 110568949
Pain in extremity 30.32 27.50 8 12122 487110 110090059
Nasopharyngitis 29.80 27.50 4 12126 394357 110182812
Prothrombin level decreased 29.40 27.50 10 12120 1800 110575369
Intestinal haematoma 29.31 27.50 7 12123 352 110576817
Anuria 29.22 27.50 23 12107 24318 110552851
Neonatal gastrointestinal disorder 29.08 27.50 5 12125 45 110577124
Hepatitis 28.71 27.50 42 12088 90012 110487157
Limited symptom panic attack 28.70 27.50 5 12125 49 110577120
Foetal heart rate disorder 28.70 27.50 5 12125 49 110577120
Disorientation 28.62 27.50 37 12093 70634 110506535
Infusion related reaction 28.48 27.50 4 12126 381158 110196011
Haemoptysis 28.34 27.50 37 12093 71317 110505852

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AA12 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Vitamin K antagonists
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
CHEBI has role CHEBI:50249 anticoagulant

Related Drugs by ATC class:

B01AA Vitamin K antagonists 9 drugs
acenocoumarolclorindionedicoumaroldiphenadioneethyl biscoumacetatephenindionephenprocoumontioclomarolwarfarin

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.43 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Arachidonate 5-lipoxygenase Enzyme IC50 5.02 CHEMBL

External reference:

IDSource
D07969 KEGG_DRUG
C0117899 UMLSCUI
CHEBI:134975 CHEBI
CHEMBL24924 ChEMBL_ID
DB13136 DRUGBANK_ID
68942 PUBCHEM_CID
C017673 MESH_SUPPLEMENTAL_RECORD_UI
4519 INN_ID
EQ35YMS20Q UNII
50097 RXNORM
005420 NDDF
19351000122101 SNOMEDCT_US

Pharmaceutical products:

None